Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriatic arthritis

Infliximab Biosimilar Receives FDA Approval

Michele B. Kaufman, PharmD, BCGP  |  April 6, 2016

The FDA has officially approved an infliximab biosimilar for the treatment of multiple autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Prescribing information is now available…

Filed under:Biologics/DMARDsDrug Updates Tagged with:FDAFood and Drug Administrationinfliximabinfliximab-dyyb

Clinical Trials: Zilretta Promising for Knee OA Pain & Golimumab Completes Phase 3 Trial

Michele B. Kaufman, PharmD, BCGP  |  March 16, 2016

In recent Phase 3 clinical trials, Zirletta proved effective in managing pain for patients with knee osteoarthritis, and subcutaneous golimumab helped patients with psoriatic arthritis achieve long-term functional improvement…

Filed under:Biologics/DMARDsDrug UpdatesResearch Rheum Tagged with:Arthritis Care & ResearchGolimumabKnee Osteoarthritis (OA)Triamcinolone acetonide (TCA)

Apremilast Proves Effective for PsA with Skin Involvement

Michele B. Kaufman, PharmD, BCGP  |  February 24, 2016

A recent Phase 3 clinical trial found apremilast safe and effective for treating patients with active psoriatic arthritis and skin symptoms who found conventional and biologic DMARDs ineffective…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:apremilastPsoriasisPsoriatic Arthritisskin

3 Clinical Trials Examine Sirukumab for RA; Plus TNF-α Combination & Monotherapies Are Compared for Treating PsA

Michele B. Kaufman, PharmD, BCGP  |  January 27, 2016

Three clinical trials are evaluating subcutaneous sirukumab for safety and efficacy in treating rheumatoid arthritis. And a study found no significant difference in persistence and remission for TNF-α monotherapy when compared with TNF-α plus conventional DMARD combination therapy for treating psoriatic arthritis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:combination therapyDisease-modifying antirheumatic drugs (DMARDs)Psoriatic ArthritisRheumatoid Arthritis (RA)sirukumabTNF inbhibitor

Secukinumab Receives 2 New Approvals: PsA & AS

Michele B. Kaufman, PharmD, BCGP  |  January 20, 2016

The FDA approved secukinumab (Cosentyx) this past week for the treatment of adults with active ankylosing spondylitis and active psoriatic arthritis. These two new approvals are based on the safety and efficacy outcomes from four placebo-controlled Phase 3 trials in more than 1,500 adults with AS or PsA…

Filed under:Biologics/DMARDsDrug Updates

New SLE Drug May Allow Patients to Reduce Steroid Use

Michele B. Kaufman, PharmD, BCGP  |  December 16, 2015

In a recent study, the use of anifrolumab in SLE patients was shown to be safe and effective, enabling some patients to decrease their oral steroids. Also, secukinumab has been approved in Europe to treat ankylosing spondylitis and psoriatic arthritis…

Filed under:Axial SpondyloarthritisBiologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:anifrolumabAnkylosing SpondylitisEuropePsoriatic Arthritissecukinumabsystemic lupus erythematosus (SLE)

Rheumatology Drug Updates, Trials, Safety Data

Michele B. Kaufman, PharmD, BCGP  |  May 1, 2014

Information on oral anticoagulant apixaban, apremilast for active psoriatic arthritis, hyaluronic acid and methotrexate injections, and drug safety updates rheumatologists need to know

Filed under:AnalgesicsBiologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:anti-inflammatoryapremilastBiologicsdrugMethotrexateOsteoarthritispatient careradiographRheumatoid arthritisrheumatologistrheumatologySafetyTofacitinib

Approval Expected for Apremilast

Richard Quinn  |  March 5, 2014

New drug shows promise in treating psoriatic arthritis, ankylosing spondylitis & psoriasis

Filed under:Axial SpondyloarthritisBiologics/DMARDsConditionsDrug UpdatesOther Rheumatic ConditionsPsoriatic Arthritis Tagged with:Ankylosing SpondylitisapremilastCelgene Corp.PsoriasisPsoriatic Arthritis

Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors

Jonida Cote, DO, Thomas Harrington, MD, Alicia Meadows, DO, Fan Lin, MD, and Androniki Bili, MD, MPH  |  November 1, 2013

Two patients with psoriatic arthritis treated with TNF-alpha inhibitor therapy develop the multisystem disease

Filed under:ConditionsOther Rheumatic ConditionsPsoriatic Arthritis Tagged with:Psoriatic ArthritisSarcoidosisTherapiesTreatmentTumor Necrosis Factor–Alpha Inhibitor

EULAR 2013: Researchers Expand Targets for PsA, OA Therapy

Thomas R. Collins  |  September 1, 2013

Experts discuss insights in the pathogenesis of psoriatic arthritis and the role of subchondral bone in osteoarthritis

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPsoriatic Arthritis Tagged with:OsteoarthritisPathogenesisPsAPsoriatic Arthritis

  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 63
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences